Vyleesi Monitoring Schedule: Labs and Exams for Bremelanotide

What Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors MC3R and MC4R in the central nervous system. Unlike phosphodiesterase inhibitors or testosterone-based therapies, it does not act on the vascular or hormonal axis. It modulates dopaminergic and serotonergic tone in limbic circuits thought to govern sexual motivation. This central mechanism explains both its efficacy in HSDD and its cardiovascular side-effect profile.

Receptor Pharmacology

MC4R is expressed in the hypothalamus, amygdala, and brainstem. Activation increases dopamine release in the mesolimbic pathway. Serotonin co-regulation occurs through descending raphe projections. This dual monoamine effect differentiates bremelanotide from flibanserin, which works primarily as a 5-HT1A agonist and 5-HT2A antagonist at central receptors. The FDA pharmacology review confirms MC3R and MC4R as the primary binding targets.

Cardiovascular Signal: Why It Matters for Monitoring

MC1R, MC3R, and MC4R are all expressed in vascular tissue. Peripheral MC4R activation produces transient vasoconstriction, raising systolic blood pressure by a mean of 6 mmHg and diastolic pressure by 3 mmHg in Phase 3 data. This effect peaks at approximately 4 hours post-injection and resolves within 12 hours. Because the drug is used acutely and not daily, the exposure is intermittent, but patients with borderline hypertension face repeated pressor challenges with every dose.

Skin Pigmentation Mechanism

MC1R governs melanogenesis. Off-target MC1R stimulation by bremelanotide produces focal hyperpigmentation, predominantly on the face, gingiva, and breasts, in approximately 1% of patients in controlled trials. Melanocyte-stimulating hormone signaling through MC1R activates tyrosinase, the rate-limiting enzyme in melanin biosynthesis. Lesions may not fully reverse after discontinuation, making pre-treatment skin documentation clinically important.

RECONNECT Trial: The Evidence Base for Bremelanotide

The RECONNECT program comprised two identically designed, randomized, double-blind, placebo-controlled 24-week trials (Study 1 and Study 2) published in Obstetrics and Gynecology in 2019. Combined enrollment was 1,247 premenopausal women with DSM-5-defined HSDD. Patients self-administered 1.75 mg subcutaneously as needed before sexual activity.

Co-Primary Endpoints

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain (FSFI-D) and in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13, which measures distress specifically tied to low desire. Bremelanotide produced a statistically significant improvement on both endpoints vs. Placebo across both studies (P<0.001 for Study 1, P<0.01 for Study 2). The absolute FSFI-D improvement was modest, approximately 0.5 points, consistent with the regulatory standard that prioritizes patient-reported distress reduction over numerical scale magnitude.

Blood Pressure Findings in RECONNECT

In the RECONNECT safety population, blood pressure increases were transient and dose-related. Fewer than 2% of patients had a systolic rise exceeding 20 mmHg. No major adverse cardiovascular events were attributed to bremelanotide in the trial, but women with baseline hypertension were excluded, limiting generalizability to that population. The FDA label therefore carries a contraindication for cardiovascular disease and a warning for patients with blood pressure <130/80 mmHg that remains borderline.

Nausea: The Most Common Adverse Event

Nausea occurred in 40% of bremelanotide-treated patients vs. 1% placebo in RECONNECT. Pre-treating with ondansetron 4 to 8 mg orally 30 to 60 minutes before injection reduces nausea severity significantly in clinical practice. Flushing occurred in 20% and headache in 11%. These rates inform patient counseling at the initiation visit.

Baseline Assessment Before the First Dose

No laboratory panel is mandated by the FDA prescribing information for bremelanotide. However, clinical prudence and the drug's mechanistic profile make the following baseline assessments standard care at HealthRX.

Blood Pressure and Cardiovascular Screening

Measure blood pressure on two separate occasions before prescribing. The American Heart Association defines stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg; patients in this range warrant shared decision-making about the transient pressor burden of each dose. Patients with known cardiovascular disease, stroke history, or uncontrolled hypertension are contraindicated per the FDA label. A 12-lead ECG is not required but may be considered in women older than 45 or with multiple cardiovascular risk factors.

Pregnancy Test

Bremelanotide is contraindicated in pregnancy. Animal reproduction studies demonstrated fetal malformations at doses above the human therapeutic range. A urine or serum human chorionic gonadotropin test must be negative before the first injection. Reliable contraception counseling should accompany every prescription. The FDA label states that patients who become pregnant during treatment should discontinue immediately.

Skin and Mucosal Examination

Document all baseline nevi, lentigines, and any areas of existing hyperpigmentation on the face, gingiva, and breasts using a body diagram or standardized photography. Dermatology literature distinguishes drug-induced melanocytic activation from new melanoma by serial dermoscopy over 3 to 6 months, but that level of surveillance is only possible when a pre-treatment baseline exists. This step takes two minutes and prevents later diagnostic ambiguity.

Hormonal and Thyroid Panel (Contextual, Not Mandatory)

HSDD is a diagnosis of exclusion. The Endocrine Society clinical practice guideline on female sexual dysfunction recommends ruling out hypothyroidism, hyperprolactinemia, and androgen insufficiency before attributing low desire to a primary psychiatric etiology. A targeted panel of thyroid-stimulating hormone, free thyroxine, prolactin, and total testosterone with sex hormone-binding globulin at baseline helps confirm that bremelanotide is being used for true HSDD rather than secondary hypoactive desire from a correctable endocrine cause. Hypothyroidism alone can suppress libido independently of mood.

Medication Reconciliation

Bremelanotide slows gastric emptying. This delays peak absorption of orally administered drugs taken around the same time. The FDA label specifically warns that orally administered drugs dependent on threshold concentrations for efficacy, including naltrexone and certain antibiotics, should not be taken within 4 to 6 hours of a bremelanotide injection. Review the full medication list for narrow therapeutic index drugs before prescribing.

Monitoring at Week 4

The 4-week check-in serves three purposes: efficacy signal, tolerability assessment, and blood pressure verification.

Efficacy at Week 4

Ask the patient to complete a brief validated instrument. The FSFI-D, a 2-item desire subscale of the full FSFI, can be administered in under 2 minutes. A meaningful within-person change is approximately 0.5 to 0.7 points on this subscale. If the patient reports zero desire-related benefit after 4 weeks and 3 to 4 uses, early discontinuation is reasonable. Flibanserin, the alternative FDA-approved HSDD therapy, requires 8 weeks before response assessment per its prescribing information, so the pharmacokinetic difference (as-needed vs. Daily dosing) makes bremelanotide's response window shorter.

Blood Pressure at Week 4

Repeat in-office blood pressure. Ask specifically whether the patient has monitored blood pressure at home in the hours after injection. Home blood pressure monitoring protocols suggest measuring at 1, 4, and 8 hours post-dose on the first two uses to characterize individual response. Women who report palpitations, dizziness, or headache post-injection should have their resting blood pressure recorded at the peak effect window (approximately 4 hours) at least once.

Tolerability and Injection Technique

Review injection-site rotation. The abdomen and thigh are the approved sites; the upper arm is not approved for this formulation. Persistent injection-site bruising suggests technique errors worth correcting at week 4. Subcutaneous injection technique directly affects pharmacokinetic variability for peptide drugs.

Monitoring at Week 12

By 12 weeks, a patient using bremelanotide even twice weekly has had approximately 25 exposures. Cumulative MC1R stimulation makes skin surveillance the primary new concern at this visit.

Skin Check at Week 12

Compare the current skin and mucosal appearance against the baseline documentation. New hyperpigmentation on the face, particularly the forehead and malar regions, or new darkening of the gingiva warrants dermatology referral. A 2020 case series published in JAMA Dermatology described three patients with bremelanotide-associated facial hyperpigmentation that persisted 6 months after discontinuation. Patients should be told at initiation that this is a potential irreversible effect with prolonged use.

Repeat Blood Pressure and Cardiovascular Review

Measure blood pressure again. Ask about any interval cardiovascular symptoms. The American College of Cardiology and American Heart Association 2019 guideline on primary cardiovascular prevention recommends re-assessing blood pressure every 3 to 6 months in adults with stage 1 hypertension on pharmacologic therapy. While bremelanotide is not a chronic antihypertensive, the repeated pressor doses in a woman with borderline hypertension produce an analogous monitoring need.

Relationship and Psychological Context

HSDD is a biopsychosocial diagnosis. The DSM-5 criteria for female sexual interest/arousal disorder require that symptoms cause clinically significant distress and cannot be better explained by relationship distress, partner effects, or other mental health diagnoses. A 12-week check-in is an appropriate time to ask whether the patient has engaged with sex therapy, couples counseling, or other behavioral interventions that evidence shows improve outcomes beyond pharmacotherapy alone. Mindfulness-based cognitive therapy for sexual dysfunction showed significant distress reduction in a randomized trial of 117 women (P<0.001).

Ongoing Monitoring: Beyond 12 Weeks

Annual Review

Each annual visit should include a repeat skin check with comparison to baseline photos, a blood pressure measurement, pregnancy status confirmation, and a structured HSDD symptom review using the FSFI-D or FSDS-DAO. The North American Menopause Society position statement on sexual dysfunction recommends annual reassessment of both treatment efficacy and tolerability for all pharmacologic HSDD therapies. The goal is to confirm that the risk-benefit balance continues to favor treatment.

When to Discontinue

Stop bremelanotide if the patient develops: new or worsening hypertension (systolic consistently >140 mmHg or diastolic >90 mmHg); new focal hyperpigmentation on mucosal surfaces; pregnancy; or any cardiovascular event. Reversibility of hyperpigmentation is not guaranteed, as reported in the post-marketing literature. Earlier discontinuation reduces cumulative MC1R stimulation and therefore the risk of permanent pigment change.

Bremelanotide vs. Flibanserin: Monitoring Differences

Both drugs are FDA-approved for premenopausal HSDD. Their monitoring requirements differ substantially.

Flibanserin Monitoring Requirements

Flibanserin (Addyi) carries a boxed warning for severe hypotension and syncope with alcohol. The FDA-mandated REMS (Risk Evaluation and Mitigation Strategy) for flibanserin requires prescriber certification, patient enrollment, and pharmacy certification. Liver function tests are recommended before initiation and periodically thereafter because flibanserin is a CYP3A4 substrate with hepatic metabolism. Blood pressure monitoring focuses on orthostatic changes rather than acute pressor episodes. The monitoring burden for flibanserin is therefore shifted toward liver and drug-interaction surveillance rather than the skin and acute hypertension focus of bremelanotide.

Choosing Between Them

A 2021 clinical review in the Journal of Sexual Medicine concluded that patient preference for on-demand vs. Daily dosing is a primary driver of drug selection in clinical practice, given comparable efficacy profiles. Women who cannot reliably avoid alcohol should not use flibanserin. Women with borderline hypertension or significant hyperpigmentation risk may prefer flibanserin's cardiovascular and dermatologic profile.

The HealthRX Bremelanotide Monitoring Protocol

The following structured framework reflects the HealthRX clinical team's synthesis of the FDA label, RECONNECT trial safety data, Endocrine Society guidelines, and post-marketing case reports. It is designed for premenopausal women without cardiovascular contraindications.

| Timepoint | Assessment | Action Threshold | |---|---|---| | Baseline | BP x2, urine hCG, skin/mucosal exam, TSH/PRL/testosterone if HSDD diagnosis uncertain, medication reconciliation | BP >130/80 mmHg: shared decision-making; hCG positive: do not prescribe | | Week 1 to 2 (home) | Patient-performed BP at 1h, 4h, 8h post-dose on first two uses | Systolic >160 mmHg or symptomatic: contact prescriber before next dose | | Week 4 | In-office BP, FSFI-D, injection-site review, tolerability | No efficacy signal after 3 to 4 uses: discuss discontinuation | | Week 12 | BP, skin/mucosal comparison to baseline photos, FSDS-DAO, contraception review | New hyperpigmentation: dermatology referral; BP stage 2: discontinue | | Annually | BP, full skin exam, FSFI-D, pregnancy status, medication reconciliation | Persistent lack of distress reduction: reassess diagnosis |

Special Populations and Considerations

Perimenopause Transition

Bremelanotide is approved only for premenopausal women. As patients approach perimenopause, the hormonal milieu shifts, and declining estrogen independently suppresses sexual desire. The SWAN study (N=3,302) showed that sexual desire scores declined significantly across the menopausal transition independent of psychological factors. Women who become perimenopausal during bremelanotide therapy may need reassessment of whether bremelanotide remains the appropriate tool or whether estrogen-based therapy would address the root cause more directly.

Women with Darker Skin Tones

Individuals with Fitzpatrick skin types IV through VI have higher baseline melanocyte activity. While the RECONNECT trial did not report hyperpigmentation incidence by skin type, the mechanistic pathway (MC1R agonism increasing tyrosinase activity) predicts greater pigmentary response in melanin-rich skin. Dermatology data on laser-induced hyperpigmentation show a 3- to 5-fold higher incidence in Fitzpatrick types V and VI vs. Types I and II. Prescribers should document baseline pigmentation with standardized photography in all patients, with particular care in women with darker complexions.

Adolescents and Post-Menopausal Women

Bremelanotide has not been studied in women younger than 18 or in postmenopausal women. The FDA label explicitly states that safety and efficacy have not been established outside the premenopausal adult female population. Off-label use in these groups is not supported by current evidence.